Good MorningEquity markets rebounded on Wednesday but it is far too soon to call the bottom. The move comes in tandem with a top in oil prices but it is far too soon to call it the end of higher prices as well. The key takeaway for traders is that WTI is still trading well above the $100 level and will be a driving force for inflation while the S&P 500 are trading below a key resistance point. The S&P 500 broke through the 4,300 level on Monday and there is still evidence of downward pressure in the charts.
The next test for the market could come as soon as Thursday in the form of the CPI. The CPI is expected to accelerate at the headline and core levels and to levels not seen in decades. The news will put added pressure on the FOMC in the face of rising wages and higher oil prices that are sure to drive inflation as soon as the present quarter. Featured: The suits might come after me for showing you this (Ad) 
|
Medical | |
On the heels of OxyContin maker Purdue Pharma asking a federal judge to approve a $6 billion nationwide settlement due to the overdose and addiction crisis, a new company will form following the U.S. Bankruptcy Court chapter 11 plan of reorganization. The resulting company is known as Knoa Pharma ... Read the Full Story |
|
From Our Partners | | Trader Graham Lindman has built a strategy around a repeating anomaly that appears in the first 60 minutes of every trading day - and it never requires holding positions overnight.
The setup has recently been refined to target up to 100% payouts by holding through the close, with 10 consecutive winning trades logged during one of the most volatile stretches since the Tariff Wars.
A new signal opportunity opens tomorrow. | | See how to join Graham Lindman's next trade before it opens |
|
Consumer Staples | |
High-Yield Deep-Value Campbell Soup Company Dips To Support
Campbells Soup Company (NYSE: CPB) is among the more attractive consumer discretionary stocks and its shares just went on sale. The stock is trading at only 15X its earnings while yielding over 3.5% with earnings improvement and dividend... Read the Full Story |
|
Retail/Wholesale | |
Buy-and-hold investing can be one of the best ways to grow your wealth over time if you possess patience and are ok with the idea of holding through some drawdowns over the years. This investment strategy is attractive for quite a few reasons, as it doesn’t require spending a lot of time act... Read the Full Story |
|
From Our Partners | | Roger Scott just unveiled a day-trading tool designed to identify the first wave of institutional buying before a full order moves through the market - potentially in minutes.
On April 14th, the tool flagged early institutional buys on HOOD at 9:45 am, delivering a 24% return in 6 minutes. Minutes later, a signal on MSTR locked in a 33% return in 12 minutes. Free access is available now. | | Secure your free pass to the real-time institutional order tracker today |
|
Consumer Staples | |
In the world of stock investing sometimes boring is good.
With the Russia-Ukraine conflict in its second week, market volatility has found a second gear. This has left many investors making tactical adjustments to protect principal. A common tactic during times of turbulence is to dial back the r... Read the Full Story |
|
Markets | | Steakhouse operator Ruths Hospitality Group (NASDAQ: RUTH) stock have illustrated relative strength amid the sell-off in benchmark indexes. The Company experienced over 60% top-line growth in Q4 2021 as it returns to sales growth despite the onset of the Omicron variant. Inflationary pressures were ... Read the Full Story |
|
From Our Partners | | Roger Scott spent twenty years on Wall Street moving billions through the market. Now he's exposing the 'empty chair' signal he says sits behind the most stunning stock moves retail investors rarely hear about.
The same signal reportedly triggered a 138% return on WMT in two weeks and a 157% return on Cencora in one week, according to his research. | | Watch Roger Scott reveal the empty chair signal today |
|
Transportation | |
REV Group May Gain Traction In Second Quarter
REV Group (NYSE: REVG) released its Q1 results and one thing is glaringly clear; supply chain constraints continue to impact both the top and bottom lines. This issue has the shares down more than 25% from their 2021 high but a reversal may be at han... Read the Full Story |
|
Auto/Tires/Trucks | |
Undervalued Stock Thor Industries Bolts Higher On Strong Results
Thor Industries (NYSE: THO) reported a blowout FQ2 and we are not surprised. Not only are there strong tailwinds blowing throughout the industry but the company has been working on capacity, building inventory, and acquiring growth... Read the Full Story |
|
Retail/Wholesale | |
U.S. stocks are on track to close lower for the third straight month. It would be the first time this has happened since the pandemic plunge of early 2020.
With no end in sight to the Russian attack on Ukraine, equity markets in other parts of the world are also on edge. The energy sector aside,... Read the Full Story |
|
Medical | |
Brilliant Biotech Plays to Consider Adding Now
While the idea of adding exposure to one of the most volatile sectors of the market during a correction might not sound great on paper, the truth is that investors should view the biotech sector as a sleeping giant that could be ready to wake up in t... Read the Full Story |
|
Basic Materials | |
Stagflation sounds like an ominous term, but the fact of the matter is that we're all experiencing it right now — inflation, plus slow or stagnant economic growth rate and a relatively high unemployment rate. Think of high inflation from 40 years ago, from the 1970s and 1980s, when oil price... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. | | View Today's Stock Pick |
|
